Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

Justin M. Richner, Brett W. Jagger, Chao Shan, Camila R. Fontes, Kimberly A. Dowd, Bin Cao, Sunny Himansu, Elizabeth A. Caine, Bruno T.D. Nunes, Daniele B.A. Medeiros, Antonio E. Muruato, Bryant M. Foreman, Huanle Luo, Tian Wang, Alan Barrett, Scott Weaver, Pedro F.C. Vasconcelos, Shannan Rossi, Giuseppe Ciaramella, Indira U. Mysorekar & 3 others Theodore C. Pierson, Pei-Yong Shi, Michael S. Diamond

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.

Original languageEnglish (US)
Pages (from-to)273-283.e12
JournalCell
Volume170
Issue number2
DOIs
StatePublished - Jul 13 2017

Fingerprint

Viruses
Vaccines
Fetus
Viral Vaccines
Glycosylation
Attenuated Vaccines
Messenger RNA
Aptitude
Fetal Death
Viral RNA
Human Development
Nanoparticles
Dams
Zika Virus
Animals
Embryonic Structures
Genes
Mothers
Association reactions
Tissue

Keywords

  • antibody
  • fetus
  • flavivirus
  • immunity
  • microcephaly
  • pregnancy
  • transmission
  • Vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., ... Diamond, M. S. (2017). Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell, 170(2), 273-283.e12. https://doi.org/10.1016/j.cell.2017.06.040

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. / Richner, Justin M.; Jagger, Brett W.; Shan, Chao; Fontes, Camila R.; Dowd, Kimberly A.; Cao, Bin; Himansu, Sunny; Caine, Elizabeth A.; Nunes, Bruno T.D.; Medeiros, Daniele B.A.; Muruato, Antonio E.; Foreman, Bryant M.; Luo, Huanle; Wang, Tian; Barrett, Alan; Weaver, Scott; Vasconcelos, Pedro F.C.; Rossi, Shannan; Ciaramella, Giuseppe; Mysorekar, Indira U.; Pierson, Theodore C.; Shi, Pei-Yong; Diamond, Michael S.

In: Cell, Vol. 170, No. 2, 13.07.2017, p. 273-283.e12.

Research output: Contribution to journalArticle

Richner, JM, Jagger, BW, Shan, C, Fontes, CR, Dowd, KA, Cao, B, Himansu, S, Caine, EA, Nunes, BTD, Medeiros, DBA, Muruato, AE, Foreman, BM, Luo, H, Wang, T, Barrett, A, Weaver, S, Vasconcelos, PFC, Rossi, S, Ciaramella, G, Mysorekar, IU, Pierson, TC, Shi, P-Y & Diamond, MS 2017, 'Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease', Cell, vol. 170, no. 2, pp. 273-283.e12. https://doi.org/10.1016/j.cell.2017.06.040
Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell. 2017 Jul 13;170(2):273-283.e12. https://doi.org/10.1016/j.cell.2017.06.040
Richner, Justin M. ; Jagger, Brett W. ; Shan, Chao ; Fontes, Camila R. ; Dowd, Kimberly A. ; Cao, Bin ; Himansu, Sunny ; Caine, Elizabeth A. ; Nunes, Bruno T.D. ; Medeiros, Daniele B.A. ; Muruato, Antonio E. ; Foreman, Bryant M. ; Luo, Huanle ; Wang, Tian ; Barrett, Alan ; Weaver, Scott ; Vasconcelos, Pedro F.C. ; Rossi, Shannan ; Ciaramella, Giuseppe ; Mysorekar, Indira U. ; Pierson, Theodore C. ; Shi, Pei-Yong ; Diamond, Michael S. / Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. In: Cell. 2017 ; Vol. 170, No. 2. pp. 273-283.e12.
@article{028fe8af70d1409787d41fcb0b3dc4a5,
title = "Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease",
abstract = "The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.",
keywords = "antibody, fetus, flavivirus, immunity, microcephaly, pregnancy, transmission, Vaccine",
author = "Richner, {Justin M.} and Jagger, {Brett W.} and Chao Shan and Fontes, {Camila R.} and Dowd, {Kimberly A.} and Bin Cao and Sunny Himansu and Caine, {Elizabeth A.} and Nunes, {Bruno T.D.} and Medeiros, {Daniele B.A.} and Muruato, {Antonio E.} and Foreman, {Bryant M.} and Huanle Luo and Tian Wang and Alan Barrett and Scott Weaver and Vasconcelos, {Pedro F.C.} and Shannan Rossi and Giuseppe Ciaramella and Mysorekar, {Indira U.} and Pierson, {Theodore C.} and Pei-Yong Shi and Diamond, {Michael S.}",
year = "2017",
month = "7",
day = "13",
doi = "10.1016/j.cell.2017.06.040",
language = "English (US)",
volume = "170",
pages = "273--283.e12",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

AU - Richner, Justin M.

AU - Jagger, Brett W.

AU - Shan, Chao

AU - Fontes, Camila R.

AU - Dowd, Kimberly A.

AU - Cao, Bin

AU - Himansu, Sunny

AU - Caine, Elizabeth A.

AU - Nunes, Bruno T.D.

AU - Medeiros, Daniele B.A.

AU - Muruato, Antonio E.

AU - Foreman, Bryant M.

AU - Luo, Huanle

AU - Wang, Tian

AU - Barrett, Alan

AU - Weaver, Scott

AU - Vasconcelos, Pedro F.C.

AU - Rossi, Shannan

AU - Ciaramella, Giuseppe

AU - Mysorekar, Indira U.

AU - Pierson, Theodore C.

AU - Shi, Pei-Yong

AU - Diamond, Michael S.

PY - 2017/7/13

Y1 - 2017/7/13

N2 - The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.

AB - The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.

KW - antibody

KW - fetus

KW - flavivirus

KW - immunity

KW - microcephaly

KW - pregnancy

KW - transmission

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85023598743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023598743&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.06.040

DO - 10.1016/j.cell.2017.06.040

M3 - Article

VL - 170

SP - 273-283.e12

JO - Cell

JF - Cell

SN - 0092-8674

IS - 2

ER -